Dupilumab, a human monoclonal antibody that blocks interleukin-4 and interleukin-13 pathways, led to histologic remission in a significantly higher percentage of children with eosinophilic esophagitis than placebo.
The New England Journal of Medicine: Search Results in Allergy/Immunology
